June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
The Efficacy of Rhopressa in Lowering Intraocular Pressure in Patients with Secondary Glaucoma
Author Affiliations & Notes
  • Elizabeth Roll
    Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, United States
  • Marko Oydanich
    Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, United States
  • Yash Shah
    Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, United States
  • Albert Khouri
    Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, United States
  • Footnotes
    Commercial Relationships   Elizabeth Roll None; Marko Oydanich None; Yash Shah None; Albert Khouri None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2847 – A0370. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elizabeth Roll, Marko Oydanich, Yash Shah, Albert Khouri; The Efficacy of Rhopressa in Lowering Intraocular Pressure in Patients with Secondary Glaucoma. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2847 – A0370.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine the efficacy of Rhopressa (Netarsudil, 0.02%) in lowering intraocular pressure (IOP) in patients with secondary forms of glaucoma.

Methods : A total of 68 patients (87 eyes) with either primary open angle glaucoma (POAG) or a secondary form of glaucoma were reviewed retrospectively over the course of one year after starting Rhopressa. The secondary glaucoma group was composed of patients with uveitic, neovascular, traumatic, congenital, and pseudoexfoliative glaucoma. Patient IOP measurements were collected at baseline, 1 month, 3 month, 6 month, and 12 month intervals. Patients that underwent surgical intervention during the study period were not included in the final data analysis. IOP levels and discontinuation rates, due to intolerance or inefficacy, were tracked and monitored at each patient visit. A two sample T-test was used to determine differences in the IOP lowering effect of Rhopressa in the POAG and secondary glaucoma groups.

Results : All patients with either POAG or secondary glaucomas were matched for age (Mean ± SD; 69.7 ± 16.5 vs. 67.3 ± 21.5; p>0.05). Both the POAG and secondary glaucoma patients exhibited significant decreases in IOP at each time point (1, 3, 6, and 12 months) when compared to each group’s baseline (p<0.05). No significant differences were observed in IOP between the POAG and secondary glaucoma groups at most time points, with the exception of the 12 month interval (p<0.05). However, both groups showed similar overall decreases in IOP from baseline after 1 year of treatment (5.8 ± 4.5 vs. 5.3 ± 7.3; p>0.05). Discontinuation rates of Rhopressa due to intolerance or inefficacy were similar in both groups and less than 10% (Table).

Conclusions : Rhopressa is similarly effective in lowering IOP in patients with secondary glaucomas compared to those with POAG. Discontinuation rates were similar in both groups, supporting Rhopressa’s utility in treating secondary forms of glaucoma.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×